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Summary.-Colchicine injected 5, 9 and 24 h respectively before initiation (using
s.c. injection of urethane for initiating action and TPA skin applications for pro-
moting action, in female ICR mice) led to a significant increase in skin tumour
incidence in the -9-h group, and an increase in percentage malignancy in both
the -5- and -9-h groups. These times corresponded to the peak of metaphase
arrest by the colchicine.
The results are discussed in relation to those of Pound and Withers (1963) and
others, who found that mitotic stimulation at the time of urethane initiating action
raised the ultimate tumour incidence; and the inference is drawn that initiating
action in mouse skin may occur during the M phase, rather than during the G1, S,
or G2 phases, as suggested by others.
THE two-stage initiation-promotion
method of skin carcinogenesis readily
lends itself to the study of the nature
of neoplastic transformation, by enabling
one (a) to distinguish compounds capable
of acting as " incomplete " carcinogens
(i.e. as initiators alone or promoters
alone) from those acting as " complete "
carcinogens; (b) to correlate each of the
separate actions with other properties
the compounds may possess; and (c) to
determine the factors which can augment
or inhibit one or other of the two stages.
(For reviews see Berenblum, 1954; Bout-
well, 1964; Hecker, 1968; Van Duuren,
1969; Berenblum, 1969, 1975).
An interesting example of the third
type of approach was the reported aug-
mentation of skin carcinogenesis when
either croton oil (Pound and Bell, 1962)
or various non-specific skin irritants
(Pound and Withers, 1963) were applied
to the skin one or two days before the
initiating stimulus (and later followed by
repeated croton oil applications, for pro-
moting action). The non-specific nature
of the pre-initiating influence, the time
relationship to initiation, and the fact
that augmentation was most pronounced
when urethane (itself a non-irritant) was
used as initiator, and far less so with
DMBA (7,12-dimethylbenz[a]anthracene)
as initiator, all pointed to the conclusion
that the mode of action of the pre-treat-
ment was to stimulate cell division
(Pound and Withers, 1963; Shinozuka
and Ritchie, 1967; Hennings, Michael and
Paterson, 1973), and by inference, that
initiation itself took place during a
mitotic cycle.
The object ofthe present investigation
was first, to seek confirmation of the
above-mentioned conclusions, using col-
chicine administered systemically as the
pre-initiating stimulus, and secondly, to
determine if possible the approximate
time during the cell cycle when initiation
occurred. The experimental set-up en-
abled us at the same time to check whether
colchicine injection, or skin applications
of the promoting agent TPA, influenced
the carcinogenic effects of urethane in
other parts of the body (induction of
lung adenomas, leukaemogenesis, etc.).I. BERENBLUM AND V. ARMUTH
MATERIALS AND METHODS
Mice.-Female ICR mice about 6 weeks
old, random-bred in the Institute's Breeding
Centre under SPF conditions, were used;
they were kept in metal cages, 5 per cage, in
an air-conditioned room at 21-25°C, fed a
well-balanced diet in the form of pellets
produced in the Institute, and provided
with tap water ad libitum.
The mice were checked daily, and
examined more thoroughly twice weekly,
when papilloma development was carefully
recorded. (Papillomas that regressed within
2 weeks of their appearance were eliminated
from the final records.) Moribund animals
were killed and they, as well as those found
dead, were examined post mortem. The
treated skins, and internal organs showing
gross alterations, were taken for histological
examination, fixed in Bouin's solution, em-
bedded in paraffin, and stained with haema-
toxylin and eosin. The diagnosis of malig-
nancy was based on macroscopical ap-
pearance, and confirmed histologically from
evidence of invasiveness.
Chemicals.-Colchicine (S. B. Penick &
Co., New York-Chicago) was made up as
a 0-2% solution in saline, and 2 mg/kg
body wt. injected s.c. (For preliminary
tests with other dosages, see below.)
For initiating action, urethane (Fluka
AG Chemische Fabrik, Buchs, Switzerland)
was dissolved in saline and 1 ml, containing
25 mg of urethane, was injected s.c.
For promoting action, the phorbol ester
TPA (a generous gift from Prof. E. Hecker,
of Heidelberg, Germany) was made up as a
0-02% solution in acetone, and approximately
0-1 ml was applied to a clipped area of
skin in the dorsal region twice weekly for
25 weeks, starting 2 weeks after initiation
with urethane. The animals were kept
under observation for a further 12 months
(with a corresponding period in the control
groups) and then killed for autopsy.
The main part of the experiment con-
sisted of 4 groups of mice treated as follows
(see Table I):
Group I (75 mice): receiving a single s.c.
injection of urethane followed by TPA
applications.
Group 11 (40 mice): as above, but pre-
ceded, 5 h before initiation, by colehicine
injection.
Group III (40 mice): as above, but
preceded, 9 h before initiation, by colchicine
injection.
Group IV (40 mice): as above, but
preceded, 24 h before initiation, by colchicine
injection.
In addition, the following control groups
were included:
Group V (20 mice): receiving urethane
alone.
Groups VI, VII and VIII (30 mice
each): receiving colchicine 5, 9, and 24 h
respectively before the urethane injection,
but not followed by TPA skin applications.
Group IX (30 mice): receiving colchicine
24 h before the start of TPA skin applica-
tions, but without the intervening urethane
initiating action.
Group X (20 mice): receiving colehicine
alone.
Group XI (20 mice): receiving TPA skin
applications alone.
Group XII (35 mice): receiving no
treatment.
RESULTS
In preliminary tests, different doses
of colchicine were administered to small
groups of mice (of the same strain as
that intended for the experiment proper),
in order to determine the optimal dose
for causing mitotic arrest, without pro-
TABLE I. Strvival in the Experimental
Groups
Group
No.
I
II
III
IV
V
VI
VII
VIII
IX
x
XI
XII
Treatment
Urethane TPA
Colchicine (- 5 h)
Urethane TPA
Colchicine (-9 h)
Urethane TPA
Colchicine (-24 h)
Urethane -- TPA
Urethane
Colchicine (-5 h)
Urethane
Colchicine ( 9 h)
Urethane
Colchicine (-24 h)
Urethane
Colchicine (-24 h)
TPA
Colchicine
TPA
Untreated control
No. of
animals
at start
75
40
40
40
20
30
30
30
30
20
20
:35
Age at
50%S
survival
(days)
280
275
342
248
421
371
334
402
258
443
457
470)
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FIG.-Schematic representation ofthe effect ofpre-initiation treatment with colchicine on two-stage
skin carcinogenesis (by urethane followed by TPA).
TABLE II.-Tumour Induction in the Skin in Groups I-IV
Cumulative tumour incidence per effective totalb
Treatmenta
U-TPA
Col. (- 5 h) U-TPA
Col. (-9 h) If-TPA
Col. (-24h) U-UTPA
Malignancy
Papillomas Carcinomas ratec Total
28/71 =39% 9/71=13% 30% 30/71=42%
12/39 =31% 17/39=43% 77%d 22/39=56%e
17/38=45% 18/38=47% 62%f 29/38=76%d
15/36=42% 2/36= 5% 12% 16/36=45%
Tumours per
animal of
effective totalb
1-05
1-18
1-81
1 05
a Col. = colchicine injection; U = urethane injection; TPA = twice weekly skin applications of TPA.
b Effective total = number of survivors in the group at the time the first tumour appears.
c Percentage of cases in which papillomas had become malignant.
d In comparison with Group I: P < 0 -001.
e In comparison with Group I: 0 10 < P < 0 20.
f In comparison with Group I: 0 01 < P < 0-02.
TABLE III.-Skin Tumour Incidence in Survivors of Groups I-IV at
the End of 25 Weeks ofPromotion
Survivors
Interval between
colchicine and
urethane injections
No colchicine
pretreatment
-5 h
-9 h
-24h
No.
mice
at start
75
40
40
40
No.
mice
49 (65%)
Mice
with
tumours
32 (42%)
30 (75%) 22 (55%)a
34 (86%) 31 (77%)b
22 (55%) 18 (45%)
a In comparison with Group I, 0-30 < P < 0 50.
b In comparison with Group I, P < 0 -01.
ducing detectable toxic side-effects. A
single s.c. injection of 2 mg/kg body wt.
in a 0.2% saline solution was found to
satisfy these requirements. Further tests
were then carried out, using the optimal
dose of colchicine, and killing the animals
after 2, 5, 9, 16, 24, and 36 h for estimating
the percentage of mitoses per unit area
of skin, in comparison to normal skin.
Mitoses were counted in skin areas of
Group
I
II
III
IV
Group
I
II
III
IV
No.
tumours
47
27
56
23
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TABLE IV.-Tumour Incidence in Organs and Tissues Other than Skin
Treatmenta
U-TPA
Col. (-5 h) -TPA
Col. (-9 h) U-TPA
Col. (- 24 h) TJ-TPA
Urethane alone
Col. (-5 h) U
Col. (9 h) U
Col. (-24 h) U
Col. (-24 h) TPA
Colchicine alone
TPA alone
UJntreated control
Lung
adenomasb
50/63=79%
32/35=91%
31/31 = 100%
20/23=87%
13/13= 100%
25/28= 89%
22/25 =88%
19/21 =90%
2/26=8%
0/20=0%
0/20=0%
6/34= 18%
Lymphoreticular
tumoursb
17/64=26-5%
8/35 =23%
7/32=22%
7/26=27%
3/16= 19%
7/28=25%
7/26=26%
1/21 =5%
0/30=0%
1/20=5%
1/20=5%
3/32 = 90/'
Tumours in other organs
4 mammary; 1 hepatoma
2 mammary
3 mammary
2 mammary
1 mammary
3 mammary
1 mammary
2 mammary
1 mammary; 1 hepatoma
a Col. = colchicine injection; U urethane injection; TPA = twice weekly skin applications of TPA.
b Calculated per effective total (survivors at first appearance of the particular tumour).
equal size, and the increase after col-
chicine treatment was calculated as per-
centages of the normal untreated skin.
The counts were made on semi-serial
sections of skins from 5 mice per group.
The percentage of mitoses at 5 and 9 h
after colchicine injection was 3'6 times
that of the untreated control skins.
The results, plotted semi-quantitatively
in the curve in the figure, agree fairly
closely with those for mouse skin reported
by Bertalanffy (1964) and others.
As in the original experiments of
Pound and Bell (1962), a single s.c.
injection of urethane was used for the
initiating stimulus, but instead of crude
croton oil for promoting action, the
active principle TPA (Hecker, 1968)
served as promoting agent in the present
experiment.
The effects of colchicine injection 5,
9, or 24 h before the initiating stimulus
(followed by repeated applications of
TPA), are summarized in Tables II and
III (Groups II, III and IV, respectively,
compared with the non-colchicine control
Group I). The slight augmentation of
skin tumour incidence in Group II
(- 5 h) is not statistically significant, but
the percentage of papillomas becoming
malignant in this group is significantly
higher than in the control group. No
augmentation is seen in Group IV (- 24
h), whether judged in terms of total
tumour incidence, or percentage of malig-
nant transformation of papillomas. The
most decisive evidence of augmentation
is seen in Group III (-9 h), in which
both the total tumour incidence and the
percentage of malignant transformation
are significantly increased. (The malig-
nant skin tumours, listed in Table II,
were the result of progression from
papillomas, in all cases except 2 (one in
Group II and one in Group III), which
appeared to have arisen as carcinoma
from the start.) As shown in the figure,
this increase corresponds more or less
to the peak of metaphase arrest in the
treated skin.
No skin tumours were detected in
the 8 control groups (V-XII), in which
one or both of the two-stage components
(initiation or promotion) were excluded
from the treatment given.
These control groups served mainly
to check whether colchicine administra-
tion, or skin applications of TPA, in
any way influenced the carcinogenic
action of urethane in other parts of the
body-notably in relation to lung aden-
oma induction and leukaemogenesis.
No demonstrable effect could be discerned
(see Table IV), though in one case (Group
VIII, in which colchicine was injected
24 h before urethane injection, but with
no subsequent TPA treatment) leukaemia
incidence was surprisingly low, taking
into consideration the fact that in the
same group the incidence oflung adenomas
Group
I
II
III
IV
V
VI
VII
VIII
Ix
x
XI
XII
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was very high. The relatively low leuk-
aemia incidence could not be attributed
to inadequate survival, which was quite
high in this group (see Table I).
DISCUSSION
The initiating phase of carcinogenesis
-the first step in neoplastic transforma-
tion-is of very short duration, most of
the long latent period oftumour induction
being taken up with the promoting phase
(Mottram, 1944; Berenblum, 1954, 1975).
Since all initiating agents, and all " com-
plete " carcinogens (or their metabolites),
have been shown to bind covalently with
DNA (Brookes and Lawley, 1964; Gosh-
man and Heidelberger, 1967; Prodi, Roc-
chi and Grili, 1970), and to act as mutagens
(see Fishbein, Flam and Falk, 1970), it
is now generally accepted that the initial
step in neoplastic transformation is the
result of a somatic cell mutation, and
that the initiating phase of carcino-
genesis must, therefore, be associated
with the mitotic apparatus of the cell.
The augmentation of two-stage car-
cinogenesis in mouse skin by stimulation
of cell division prior to the initiating
phase (Pound and Withers, 1963; Hen-
nings et al., 1973), is in keeping with
this view; and our present results, using
colchicine as a means ofcausing accumula-
tion of cells in metaphase at the time of
initiation, also support it.
There is, however, no agreement about
the exact phase of the cell cycle when
the initiating action takes effect. Accord-
ing to Frei and Ritchie (1964), Marquardt
(1974), and others, it is during the S
phase-i.e. at the time ofDNA replication
in the cell; according to McCarter and
Quastler (1962), Banerjee (1965), and
Simard, Cousineau and Daoust (1968),
it takes place during the G2 phase-i.e.
after completion of the S phase, but
before cell division; whereas Magee (1974)
and Bertram and Heidelberger (1974) have
found evidence for the initiating phase
operating at the G1-S boundary (immedi-
ately before DNA replication). Yuspa et
al. (1969) observed more DMBA binding
with non-replicating epidermal DNA than
with replicating DNA: which argues
against S-phase involvement. These con-
flicting results may possibly be attributed
to the use of different target organs
(skin, liver, etc.) and of different experi-
mental procedures and systems of testing
(in vivo, in vitro, etc.).
The present results suggest yet another
possibility: that the initiating phase of
carcinogenesis in mouse skin takes place
during the M phase, since augmentation
was most pronounced when colchicine
was injected 9 h before urethane initiating
action, corresponding to the peak of
metaphase arrest (see Fig.), and taking
into account the rapid metabolic break-
down of urethane and its elimination
from the body (Cividalli, Mirvish and
Berenblum, 1965). The fact that the
peak period of effective augmentation
of carcinogenesis is -9 h with colchicine,
and ranges over a much longer period
with croton oil or other irritants (Pound
and Bell, 1962; Pound and Withers,
1963; Hennings et al., 1973), is easily
explicable by the fact that induced
stimulation of cell division by skin
irritants is a relatively slow process,
whereas mitotic arrest with colchicine is
very rapid.
No striking influence on urethane
carcinogenesis could be detected in other
organs as a consequence of colchicine
injection and/or TPA skin applications
(see Table IV). The unexpectedly low
incidence of leukaemia in Group VIII
(colchicine injection 24 h before urethane
injection) is probably a chance phenom-
enon, since a raised incidence of leuk-
aemia comparable to the effect ofurethane
alone, or even higher, was found in
Group IV (colchicine injection 24 h before
urethane injection, but followed, in this
case, by TPA skin applications).
This work was partly supported by
the Bundesminister fur Forschung und
Technologie, German Federal Republic,
under a joint contract with the Deutsches
Krebsforschungszentrum, Heidelberg.
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